Published Date: 08 Apr 2023
Second boosters will be allowed starting 4 months after someone receives an initial dose of the latest version of COVID protection, called a bivalent booster.
Read Full NewsThe recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.
The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.
1.
PSMA-PET/CT Detects Metastatic Prostate Cancer Missed by Other Imaging
2.
Early, virtual palliative care feasible for advanced lung cancer
3.
Lung cancer screening adherence rates decline annually after baseline screening
4.
Traveling to Die: The Latest Form of Medical Tourism
5.
Transplantation Fails to Improve Survival in Mantle Cell Lymphoma
1.
Case Study: Diagnostic and Therapeutic Challenges in Aplastic Anemia Mimicking Hypoplastic Myelodysplastic Syndrome
2.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
3.
Leptomeningeal Carcinomatosis: Symptoms, Causes, and Treatment Options
4.
Lactic Acid-Linked lncRNAs in Wilms Tumor: Decoding the Tumor Microenvironment & Prognosis
5.
Unlocking the Secret to Accurate ANC Calculation with This Informative Blog Post
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation